Biocon Ltd Q2FY11 Result Update

Biocon Ltd Q2FY11 Result Update

Ø  Biocon registered strong 17% YoY increase in revenues with across-theboard growth in all core businesses like Insulins, Immunosuppressants,

 Statins and Branded Formulations. Quarter revenues increased by ~INR 1 bn to INR 6.8 bn on YoY basis.

Ø  EBITDA increased 27% YoY and 9% QoQ to ~INR 1448 mn in Q2 FY11. EBITDA margin improved by 164 bps to 21.3% on YoY basis, due to

 reduction in operating expense.

Ø  Net Profit also improved by 20.4% YoY and 16.3% QoQ to ~INR 892 mn. Slower growth was seen due to reduction in other income. PAT margin

 improved marginally to 13.1% from 12.8% same period last year.

Outlook & Valuation

Stock is currently trading at 22x its FY12E earnings. We rerate the stock to BUY with a fresh price target of INR 560.

Thanks & Regards,

Unicon Wealth Research